Bioequivalence and Bioavailability Forum

Subject	Author	Posted	Rep.	last R.	Views
Normal Reference Range Vs Pre-defined site normal values Normal Reference Range Vs Pre-defined site normal values Hb level OT Hb level Hb level Hb level Hb level Hb level Participation databases Participation databases Participation databases Participation databases Participation databases Participation databases National databases‽ Great discussion Great discussion Great discussion WTF ? Great discussion National databases‽	cakhatri	2019-12-17 11:35	21	2020-01-02 17:42	13,396
Should those subjects have only one period data be included in BE analysis? No way! But... No way! But... No way! But... No way! But... No way! But... EMA guideline: no way...: EMA guideline: no way...: Slightly off topic, but related :-) Slightly off topic, but related :-) Slightly off topic, but related :-) Slightly off topic, but related :-) Slightly off topic, but related :-) 2.220446e-16 ≈ 0 The optional tolerance argument 2.220446e-16 ≈ 0 Sum of residuals ~ ε Sum of residuals ~ ε Wrong terminology Sum of residuals ~ ε	ssussu	2019-12-06 10:58	19	2019-12-28 12:55	10,504
BE study design issue 1×2 ≠ 2×1 1×2 ≠ 2×1 1×2 ≠ 2×1 x ◦ y = y ◦ x? BE study design issue ER vs. IR ER vs. IR	jag009	2019-12-13 23:26	7	2019-12-19 08:01	6,018
Reference drugs for triple combination test drug in Russia Reference drugs for triple combination test drug in Russia Reference drugs for triple combination test drug in Russia Reference drugs for triple combination test drug in Russia Reference drugs for triple combination test drug in Russia Reference drugs for triple combination test drug in Russia OT: Speak with the regulator Reference drugs for triple combination test drug in Russia Reference drugs for triple combination test drug in Russia Reference drugs for triple combination test drug in Russia Reference drugs for triple combination test drug in Russia Reference drugs for triple combination test drug in Russia WHO FDC Scenario 2 WHO FDC Scenario 2 EEU FDC Scenario 5.3.2 EEU FDC Scenario 5.3.2 EMA example Reference drugs for triple combination test drug in Russia Reference drugs for triple combination test drug in Russia Reference drugs for triple combination test drug in Russia	Beholder	2019-11-13 12:47	19	2019-11-21 13:02	10,351
Bicalutamide having Long Half Life Bicalutamide: Crossover not realistic Bicalutamide: Crossover not realistic	udayk	2019-10-04 12:06	2	2019-10-10 07:10	4,069
Two 2x2 and one 6x3 crossover design Two 2x2 and one 6x3 crossover design	qzhou	2019-09-24 04:20	1	2019-09-24 08:57	4,113
Equivalency Studies for Injectables	ilee9009	2019-09-20 10:24	0		2,366
suggest suitable Sequence for Reference replicate and Two Different Test? Not sure whether it makes sense Not sure whether it makes sense Not sure whether it makes sense Not sure whether it makes sense	SP	2019-07-29 14:31	4	2019-08-05 07:27	4,974
Steady State achievement	rajasekharkakarla	2019-07-03 10:02	0		2,541
Bio Batch Size Bio Batch Size Bio Batch Size Bio Batch Size	fedesalas	2018-09-12 17:46	3	2019-05-11 13:27	7,337
Can we have two primary objectives? Can we have two primary objectives?	Achievwin	2019-01-24 17:50	1	2019-01-25 08:55	3,199
Acetylsalicyclic Acid + Glycine Tablet	Ramesh Ramalingam	2019-01-21 11:33	0		2,059
Dextromethorphan 90 mg in a single dose Dextromethorphan 90 mg in a single dose	heritage	2018-11-24 15:36	1	2018-11-26 09:33	4,150
BMI BMI limits BMI limits BMI limits BMI limits BMI limits	Amira Gouda	2018-10-30 10:48	5	2018-10-31 12:59	5,523
flibanserin: sample size	mokhtar saleh	2018-10-28 12:34	0		2,673